A microorganism and its application

By screening and expressing microorganisms Phytobacter sp. HAD-10, which is a microorganism that is highly efficient hyaluronic acid lyase, the problems of low activity and poor ability of hyaluronic acid lyase in the prior art are solved, and the efficient degradation of hyaluronic acid and a variety of glycosamines are achieved. Stability and wide application of glycans.

CN118406592BActive Publication Date: 2024-11-19BEIJING HUAYAN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410484190.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-22
Publication Date
2024-11-19
Estimated Expiration
2044-04-22

AI Technical Summary

Technical Problem

The existing hyaluronic acid lyases are derived from animals, and they have problems with low vitality, high cost and animal virus safety risks. In addition, enzymes from microbial sources have different abilities in degrading hyaluronic acid, making it difficult to decompose efficiently.

Method used

Phytobacter sp. HAD-10, a microorganism that is highly efficient in cleavage of hyaluronic acid and chondroitin sulfate, was screened from the soil, and prokaryotic expression was performed by analyzing its amino acid sequence to obtain efficient hyaluronic acid lyase for degradation of glycosamine Glycan.

Benefits of technology

It has achieved efficient degradation of hyaluronic acid and a variety of glycosaminoglycans, with good stability and is widely used in agriculture, clinical medicine, food health care and cosmetics fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118406592B_ABST
    Figure CN118406592B_ABST
Patent Text Reader

Abstract

The present invention provides a microorganism and application thereof. The microorganism is separated from soil, can effectively degrade glycosaminoglycan, has the advantages of high catalytic efficiency, good stability, etc., is conducive to the development and utilization of small molecular weight glycosaminoglycan products, and has broad application prospects in agriculture, clinical medicine, food health care and cosmetics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a microorganism separated from soil and its application in agriculture and clinical medicine. Background Art

[0002] There are two major categories of hyaluronidases. One is hyaluronate hydrolase, which comes from animals; the other is hyaluronate lyase, which comes from microorganisms. Although animal-derived enzymes can decompose hyaluronic acid, the final products are mainly tetrasaccharides and hexasaccharides, with low activity, high cost, and animal virus safety risks. Although enzymes derived from microorganisms can decompose more thoroughly than enzymes derived from animals, different microorganisms have completely different utilization of carbon sources, resulting in significant differences in their ability to degrade hyaluronic acid.

[0003] In this regard, the present application screened a microorganism from the soil that can efficiently cleave hyaluronic acid, which can not only cleave hyaluronic acid but also cleave chondroitin sulfate. The amino acid sequence of the enzyme that efficiently cleaves hyaluronic acid in the microorganism was further obtained through analysis, and after prokaryotic expression, it still has the cleavage ability. Summary of the invention

[0004] Specific:

[0005] In a first aspect of the present invention, a microorganism is provided, wherein the microorganism is a plant endophyte (Phytobacter sp.) HAD-10, and the microorganism is deposited in the General Microbiology Center (CGMCC) of the China Microorganism Culture Collection Administration on February 22, 2024, with a deposit number of CGMCC No. 29875.

[0006] The storage address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0007] The nucleotide sequence of the 16S rRNA of the microorganism is shown in SEQ ID NO: 1.

[0008] The second aspect of the present invention provides a method for degrading glycosaminoglycans, which comprises using the above-mentioned microorganism.

[0009] Preferably, the glycosaminoglycan comprises β1-3 glycosidic bonds and / or β1-4 glycosidic bonds.

[0010] Preferably, the glycosaminoglycan comprises one or more of hyaluronic acid, dermatan sulfate, keratan sulfate, heparin, heparan sulfate or chondroitin sulfate.

[0011] Preferably, the chondroitin sulfate includes one or more of CS-A, CS-B, CS-C, CS-D, CS-E, CS-F, CS-H, CS-K, CS-L or CS-M.

[0012] In a specific embodiment of the present invention, the chondroitin sulfate includes one, two or three of CS-A, CS-C or CS-D.

[0013] Preferably, the microorganism expresses SEQ ID NO: 3 or an amino acid sequence having 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more homology with SEQ ID NO: 3.

[0014] Preferably, the genome of the microorganism contains SEQ ID NO: 2 or a nucleotide sequence having 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more homology with SEQ ID NO: 2.

[0015] Preferably, the method comprises culturing the above-mentioned microorganism and mixing the culture supernatant with the glycosaminoglycan to be degraded.

[0016] Further preferably, the method comprises culturing the above-mentioned microorganism, collecting the supernatant, centrifuging and collecting the precipitate; and mixing the precipitate with the glycosaminoglycan to be degraded.

[0017] Preferably, the centrifugation may be performed once or twice or more.

[0018] Preferably, the process further comprises adding ammonium sulfate before centrifugation, preferably adding 80% ammonium sulfate.

[0019] Preferably, the mixing reaction time is 1-5 h, preferably 1-3 h, for example 1, 2, 3, 4, 5 h.

[0020] Preferably, the mixed reaction temperature is 30-40°C, preferably 35-40°C, for example 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40°C.

[0021] Preferably, the method further comprises resuspending the precipitate. Preferably, the resuspending is performed using a suspension buffer, preferably, the suspension buffer is any buffer suitable for culturing cells, such as PBS, Tris buffer or glycine buffer. In a specific embodiment of the present invention, the suspension buffer is PBS.

[0022] In a specific embodiment of the present invention, the method comprises:

[0023] 1) culturing the microorganism in a shake flask and collecting the supernatant (preferably the extracellular supernatant);

[0024] 2) adding ammonium sulfate (preferably 80% ammonium sulfate) to the supernatant collected in 1), centrifuging and collecting the precipitate;

[0025] 3) resuspending the precipitate collected in 2);

[0026] 4) Adding glycosaminoglycan to be degraded.

[0027] Preferably, the method comprises mixing a protein comprising SEQ ID NO: 3 or an amino acid sequence having 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more homology to SEQ ID NO: 3 with the glycosaminoglycan to be degraded.

[0028] Preferably, the method for preparing a protein comprising SEQ ID NO: 3 or an amino acid sequence having 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more homology to SEQ ID NO: 3 comprises:

[0029] introducing a nucleotide sequence encoding SEQ ID NO: 3 or an amino acid sequence having 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more homology to SEQ ID NO: 3 (preferably comprising the nucleotide sequence of SEQ ID NO: 2) into a host cell to induce expression thereof;

[0030] Preferably, the preparation method further comprises purification.

[0031] Preferably, the reaction time after adding the glycosaminoglycan to be degraded is 1-5 h, preferably 1-3 h, for example 1, 2, 3, 4, 5 h.

[0032] Preferably, the reaction temperature after adding the glycosaminoglycan to be degraded is 30-40°C, preferably 35-40°C, for example 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40°C.

[0033] Preferably, the glycosaminoglycan is hyaluronic acid, and the degradation product includes small molecule hyaluronic acid. Preferably, the small molecule hyaluronic acid includes hyaluronic acid oligosaccharide or GalNAc monosaccharide.

[0034] The third aspect of the present invention provides small molecule hyaluronic acid obtained by the above method for degrading glycosaminoglycans.

[0035] In a fourth aspect, the present invention provides a use of the above-mentioned microorganism, or SEQ ID NO: 3 or an amino acid sequence having more than 80% homology with SEQ ID NO: 3, or a protein comprising the amino acid sequence shown in SEQ ID NO: 3,

[0036] The applications described include:

[0037] 1) Application in the degradation of glycosaminoglycans;

[0038] 2) Application in the preparation of small molecule hyaluronic acid;

[0039] 3) Application in the preparation of products that inhibit tumor spread, promote wound healing, promote bone formation, promote angiogenesis, regulate immunity, resist oxidative free radicals or repair cell damage.

[0040] Preferably, the product comprises one or more of medicine, food or cosmetics.

[0041] Preferably, the product comprises a product of glycosaminoglycan degradation by the above-mentioned microorganism, or SEQ ID NO: 3 or an amino acid sequence having more than 80% homology with SEQ ID NO: 3, or a protein comprising the amino acid sequence shown in SEQ ID NO: 3, such as small molecule hyaluronic acid.

[0042] Preferably, the glycosaminoglycan comprises β1-3 glycosidic bonds and / or β1-4 glycosidic bonds.

[0043] Preferably, the glycosaminoglycan comprises one or more of hyaluronic acid, dermatan sulfate, keratan sulfate, heparin, heparan sulfate or chondroitin sulfate.

[0044] Preferably, the chondroitin sulfate comprises one or more of CS-A, CS-B, CS-C, CS-D, CS-E, CS-F, CS-H, CS-K, CS-L or CS-M. In a specific embodiment of the present invention, the chondroitin sulfate comprises one, two or three of CS-A, CS-C or CS-D.

[0045] Preferably, the small molecule hyaluronic acid comprises hyaluronic acid oligosaccharide or GalNAc monosaccharide;

[0046] Preferably, the GalNAc monosaccharide includes saturated GalNAc monosaccharide and / or unsaturated GalNAc monosaccharide.

[0047] Preferably, the hyaluronic acid oligosaccharide includes saturated hyaluronic acid oligosaccharide and / or unsaturated hyaluronic acid oligosaccharide.

[0048] Preferably, the hyaluronic acid oligosaccharide comprises even-numbered oligosaccharides;

[0049] Preferably, the even-numbered oligosaccharides include one or more of hyaluronic acid disaccharide, hyaluronic acid tetrasaccharide, hyaluronic acid hexasaccharide, hyaluronic acid octasaccharide or hyaluronic acid decasaccharide.

[0050] Preferably, the hyaluronic acid oligosaccharides include odd-numbered oligosaccharides;

[0051] Preferably, the odd-numbered oligosaccharide comprises one or more of hyaluronic acid trisaccharide, hyaluronic acid pentasaccharide, hyaluronic acid heptasaccharide or hyaluronic acid nonasaccharide.

[0052] Preferably, the drug comprises the above-mentioned microorganism, or SEQ ID NO: 3 or an amino acid sequence having more than 80% homology with SEQ ID NO: 3, or a protein comprising the amino acid sequence shown in SEQ ID NO: 3, or a product of glycosaminoglycan degradation by the above-mentioned microorganism, or SEQ ID NO: 3 or an amino acid sequence having more than 80% homology with SEQ ID NO: 3, or a protein comprising the amino acid sequence shown in SEQ ID NO: 3.

[0053] Preferably, the drug further comprises pharmaceutically acceptable excipients.

[0054] Preferably, the pharmaceutically acceptable excipients include one or a combination of two or more of a carrier (e.g., an adsorption carrier), an excipient, a diluent, a lubricant, a wetting agent, an emulsifier, a preservative, an antioxidant, a buffer, an antibacterial agent, a suspending agent, a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, a surfactant, a suspending agent, a solubilizer, a thickener or a stabilizer.

[0055] Preferably, the drug may be in the form of any one of syrup, elixir, suspension, powder, granule, tablet, capsule, lozenge, aqueous solution, cream, ointment, lotion, gel or emulsion, or a combination of two or more thereof.

[0056] Preferably, the preparation type of the medicine is preferably a unit dose preparation. The amount of the active pharmaceutical ingredient in the unit dose preparation can be changed or adjusted from 0.001 mg to 1000 mg (preferably 0.1 mg to 500 mg, further preferably 30 mg to 100 mg, such as 0.001, 0.01, 0.1, 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 mg), depending on the specific application and effectiveness of the active ingredient. According to the needs of a specific embodiment, the composition may also include other suitable therapeutic agents.

[0057] The drug is suitable for enteral or parenteral administration.

[0058] Preferably, preparations suitable for enteral administration, such as oral administration, enteral administration or administration via catheter include one or more of an oral agent (e.g., capsules, sachets, pills, tablets, lozenges, powders, granules, aqueous or non-aqueous solutions or suspensions, water-in-oil or oil-in-water emulsions, elixirs or syrups), a rectal suppository or a rectal enema.

[0059] Preferably, preparations suitable for parenteral administration, such as by intravenous, intramuscular, intradermal and subcutaneous routes of administration, include aqueous and non-aqueous isotonic sterile injections, which may contain antioxidants, buffers, bacteriostats and solutes that make the preparation isotonic with the recipient's blood, and aqueous and non-aqueous sterile suspensions, which may contain suspending agents, solubilizers, thickeners, stabilizers and preservatives. The preparations may be present in unit doses or in multi-dose sealed containers such as ampoules and vials. Solutions and suspensions for injection may be prepared from sterile powders, granules and tablets of the types previously described.

[0060] Preferably, the food contains the above-mentioned microorganism, or SEQ ID NO: 3 or an amino acid sequence having more than 80% homology with SEQ ID NO: 3, or a protein comprising the amino acid sequence shown in SEQ ID NO: 3, or a product of glycosaminoglycan degradation by the above-mentioned microorganism, or SEQ ID NO: 3 or an amino acid sequence having more than 80% homology with SEQ ID NO: 3, or a protein comprising the amino acid sequence shown in SEQ ID NO: 3.

[0061] Preferably, the food further comprises auxiliary materials acceptable in the food field.

[0062] Preferably, the excipients acceptable in the food field include one or a combination of two or more of a carrier (such as an adsorption carrier), an excipient, a diluent, a lubricant, a wetting agent, an emulsifier, a suspension stabilizer or a preservative.

[0063] The types of food described in the present invention are not particularly limited and can be any known food, for example, dairy products, biscuits, cakes, beverages, health products, etc.

[0064] Preferably, the food is in at least one form selected from solid, dairy, solution, powder and suspension products.

[0065] Preferably, the cosmetic contains the above-mentioned microorganism, or SEQ ID NO: 3 or an amino acid sequence having more than 80% homology with SEQ ID NO: 3, or a protein comprising the amino acid sequence shown in SEQ ID NO: 3, or a product of glycosaminoglycan degradation by the above-mentioned microorganism, or SEQ ID NO: 3 or an amino acid sequence having more than 80% homology with SEQ ID NO: 3, or a protein comprising the amino acid sequence shown in SEQ ID NO: 3.

[0066] Preferably, the cosmetics contain auxiliary materials acceptable in the cosmetics field.

[0067] Preferably, the excipients acceptable in the cosmetic field include solvents, solubilizers, preservatives, antioxidants, pH adjusters, penetration enhancers, oils, moisturizers, thickeners, chelating agents, skin feel regulators, surfactants, emulsifiers, amino acids, propellants / propellants, flavors, pigments, and other functional additives, or a combination of two or more thereof.

[0068] Preferably, the dosage form of the cosmetic comprises one or more of a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a facial cleanser, a liquid foundation (such as a powder liquid foundation, an emulsion liquid foundation or a wax liquid foundation), a facial mask, a massage cream or a spray.

[0069] The term "homology" as used in the present invention refers to that in terms of the use of amino acid sequences or nucleotide sequences, those skilled in the art can adjust the sequences according to actual work needs, while ensuring that the structures or functions are similar to those of known sequences, so that the sequences used have (including but not limited to) 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36% compared to the sequences obtained by the prior art. , 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identity.

[0070] The "and / or" described in the present invention includes all combinations of items connected by the term, and each combination should be deemed to have been listed separately herein. For example, "A and / or B" includes "A", "A and B" and "B". For another example, "A, B and / or C" includes "A", "B", "C", "A and B", "A and C", "B and C" and "A and B and C".

[0071] The term “include” or “comprising” described in the present invention is an open description, which includes the specified components or steps described and other specified components or steps that will not be substantially affected.

[0072] The "small molecule hyaluronic acid" described in the present invention refers to a hyaluronic acid with a molecular weight ranging from 5kDa to 50kDa, preferably less than 10kDa, such as hyaluronic acid oligosaccharide or GalNAc monosaccharide.

[0073] Beneficial effects of the present invention:

[0074] The present invention screens out a microorganism capable of effectively degrading glycosaminoglycan from the soil, and has the advantages of high catalytic efficiency and good stability in degrading glycosaminoglycan. It is also found that the microorganism can degrade multiple glycosaminoglycans at the same time, for example, hyaluronic acid and chondroitin sulfate (for example, one or more of CS-A, CS-C or CS-D) at the same time, and has broad application prospects in agriculture, clinical medicine, food health care and cosmetics. BRIEF DESCRIPTION OF THE DRAWINGS

[0075] The embodiments of the present invention are described in detail below with reference to the accompanying drawings, wherein:

[0076] Figure 1 :Blast comparison results;

[0077] Figure 2 : Colony morphology of HAD-10 strain;

[0078] Figure 3 :Microscopic examination of HAD-10 strain;

[0079] Figure 4 : Absorbance of extracellular crude enzyme reaction solution of HAD-10 strain at A540;

[0080] Figure 5 :Sample evolution analysis of HAD-10 strain based on 16S rRNA;

[0081] Figure 6 :Sample evolution analysis of HAD-10 strain based on housekeeping genes;

[0082] Figure 7: Agarose gel electrophoresis of the recombinant vector;

[0083] Figure 8 :Colony PCR image;

[0084] Fig. 9 :SDS-PAGE of HAlyase1;

[0085] Fig.10 : TLC characterization of the polysaccharide cleavage ability of HAlyase1. DETAILED DESCRIPTION

[0086] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0087] Example 1 Strain screening, identification and acquisition of hyaluronan lyase sequence

[0088] 1. The microorganisms in the soil of the Qufu factory were screened to obtain a strain with the ability to degrade hyaluronic acid (named HAD-10).

[0089] (1) The soil sample was resuspended in sterile water and inoculated into HA inorganic nitrogen source liquid culture medium. The culture was shaken at 37°C and 220 rpm for 2-3 days. The culture was repeated 2-3 times to observe the change in the viscosity of the culture medium.

[0090] (2) The bacterial solution was diluted in a gradient manner and 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 200 μL of the gradient was respectively transferred to HA inorganic nitrogen source solid culture medium, and three parallel plates were set up for inverted culture at 37°C for 2-3 days.

[0091] (3) Use the BSA-acetic acid method to observe whether there are strains that produce clearing zones.

[0092] (4) Streak the positive colonies obtained in the initial screening on an LB plate for isolation and purification, and repeat this three times until the morphology of the single colonies on the plate is consistent.

[0093] (5) After purification, the single colonies were inoculated into HA as the sole carbon source inorganic salt culture medium for re-screening. After the purified strains were cultured in HA liquid culture medium for 3 hours, it was found that the HA liquid culture medium of the HAD-10 strain changed from a gel-like state to a fluid state within 1 hour, indicating that this strain has the ability to efficiently degrade HA.

[0094] 2. Sequence the 16S rDNA sequence of HAD-10 strain.

[0095] The whole genome of the HAD-10 strain was extracted; the 16S rDNA gene of the strain was amplified by PCR using universal primers 27F (SEQ ID NO: 4: 5'-AGAGTTTGATCCTGGCTCAG-3') and 1492R (SEQ ID NO: 5: 5'-TACGACTTAACCCCAATCGC-3') of 16S rDNA, and the 16S rDNA sequence was obtained by sequencing as shown in SEQ ID NO: 1. At the same time, the 16S rDNA of the strain was BLASTed on the NCBI website to obtain homology information, and it was found that the 16S rDNA sequence of the strain had a sequence similarity of about 99% with Citrobacter bitternis, Phytobacter diazotrophicus and Phytobacter ursingii (see Figure 1 ).

[0096] The HAD-10 strain was identified as a plant endophyte (Phytobacter sp.) and was deposited in the General Microbiology Center of the China Microorganism Culture Collection (CGMCC) on February 22, 2024. The deposit number is: CGMCC No. 29875, and the deposit address is: No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing.

[0097] 3. Observe the single colony morphology of HAD-10 strain and perform microscopic examination on it.

[0098] The HAD-10 strain was spread on the LB plate in gradient dilutions to observe the single colony morphology of the strain (the colony edge was wrinkled, the colony color was milky white, and the colony morphology was flat and round); Gram staining was performed on the strain, and microscopic examination revealed that the strain was a rod-shaped Gram-negative bacterium. The colony morphology diagram is shown in Figure 2 , see the microscopic examination results. Figure 3 .

[0099] 4. Extraction of extracellular crude enzyme solution of HAD-10 strain.

[0100] The HAD-10 strain was inoculated into 50 mL of LB liquid culture medium and cultured in a shake flask at 37°C; the extracellular supernatant of the strain was collected; 80% ammonium sulfate was added to the extracellular supernatant, centrifuged and the precipitate was collected; the precipitate was resuspended in PBS buffer to prepare HAD-10 extracellular crude enzyme solution; the extracellular crude enzyme concentration was detected using a BCA quantitative kit, and the enzyme concentration was 3.36 mg / mL.

[0101] 5. Determine the polysaccharide utilization capacity of HAD-10 extracellular crude enzyme solution.

[0102] 5 mg / mL hyaluronic acid (HA), chitosan (CH), chondroitin sulfate A (CS-A), chondroitin sulfate C (CS-C), chondroitin sulfate D (CS-D), heparin (Hep), and xanthan gum (XG) were used as substrates, 1 mg / mL crude enzyme solution was added, and the reaction was carried out at 37°C for 2 h. The absorbance of the reaction solution at A540 was measured, and it was found that the absorbance value of the reaction solution was larger than that of the control (see Figure 4 and Table 1), it was found that the extracellular crude enzyme of strain HAD-10 had the ability to cleave / hydrolyze HA, CS-A, CS-C, and CS-D.

[0103] Table 1

[0104] HA CS-A CS-C CS-D <![CDATA[A 540 Compare]]> 0.312 0.369 0.351 0.429 <![CDATA[A 540 Reactions]]> 0.964 0.544 0.455 0.562

[0105] 6. Conduct genetic evolution analysis on HAD-10 strain.

[0106] The MEGA software was used to construct a phylogenetic tree based on the 16S rRNA sequence and housekeeping gene of HAD-10 and the 16S rRNA and housekeeping gene sequences of other homologous strains to obtain the evolutionary relationship. The results of the evolutionary analysis based on 16S rRNA can be found in Figure 5 ; For the results of evolutionary analysis based on housekeeping genes, see Figure 6 .

[0107] 7. Perform whole genome sequencing on HAD-10 strain and discover the hyaluronan lyase gene.

[0108] The HAD-10 strain was sent to Shanghai Meiji Biotechnology Co., Ltd. for full gene sequencing to obtain the gene annotation of this strain. According to the gene annotation information, the gene sequence of hyaluronan lyase was obtained as shown in SEQ ID NO: 2. This lyase was named HAlyase1, and its protein sequence is shown in SEQ ID NO: 3.

[0109] Example 2 Heterologous expression, purification and enzyme activity detection of hyaluronan lyase HAlyase1 gene

[0110] 1. Heterologous expression of hyaluronan lyase HAlyase1 gene.

[0111] The HAlyase1 gene was cloned into the vector pET-15b, and the sequencing was correct. The HAlyase1-pET-15b recombinant plasmid was successfully constructed (see agarose gel electrophoresis for details). Figure 7 After the construction is successful, the plasmid is transformed into Escherichia coli BL21. The colony PCR results are shown in Figure 8 .

[0112] 2. Expression and purification of hyaluronan lyase protein.

[0113] In 50 mL LB medium (10 g / L trypsin, 5 g / L yeast extract and 10 g / L sodium chloride), add 100 μg / mL ampicillin (Amp), inoculate the E. coli culture containing the HAlyase1 recombinant plasmid, and culture it overnight at 37°C with vigorous shaking at 220 rpm. Inoculate the overnight culture into 1 L LB medium containing 100 μg / mL Amp and culture it at 37°C with 220 rpm until the OD reaches 0. 600 The value reached 0.6-0.8. Then IPTG (0.4mM) was added to induce the expression of HAlyase1, and cultured at 16℃, 180rpm for 16-20 hours. Bacteria were collected by centrifugation at 4℃, 5000×g for 10min. The bacteria were broken by ultrasound, and the cell debris was removed by centrifugation at 4℃, 24000×g for 30min. The supernatant was collected and purified by Ni column. The SDS-PAGE results of HAlyase1 can be found in Fig. 9 .

[0114] 3. Analysis of the polysaccharide cleavage ability of hyaluronan lyase HAlyase1.

[0115] 5 mg / mL hyaluronic acid (HA), chitosan (CH), chondroitin sulfate A (CS-A), chondroitin sulfate C (CS-C), chondroitin sulfate D (CS-D), heparin (Hep), and xanthan gum (XG) were used as substrates, and 1 mg / mL HAlyase1 was added. The reaction was carried out at 37°C. After 10 minutes, the reaction products were analyzed by TLC. It was found that HAlyase1 had high cleavage activity against HA and could also cleave CS-A, CS-C, and CS-D (see Fig.10 ), the cleavage products obtained are all disaccharides.

[0116] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0117] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

[0118] The nucleotide sequences and amino acid sequences involved in this application are as follows:

[0119] SEQ ID NO:1

[0120]

[0121] SEQ ID NO:2

[0122]

[0123] SEQ ID NO:3

[0124] MGSVHAQIATENVNLPVVKSTTTTSTQQQHIIERMRDTWRQNFVPSGPAAPELSAEYVASLNKTANIFWKGIDKNTPAGQLWADTVLDSESTSGRLKLGTTLYTVYQRLFTLAKAWATPGTDLYKNAQLNTVLKSALINLNQDYYNDQTPEWGNWWNWELGISRSVNNTLVILYDDLPSTLIDKYNLATRHFVRDPRYLAEGSGAPYSTTKNAFTSTGGNRIDSAMVVFVRGLLANDPGEISAAVTSVPEVLNTVQSGDGFYKDGSFIQHKDLPYSGTYGQVLLNGLGLIKNSVAGTPWDFSVEDNRRIYDVIRQAFLPLLHEGKMPDAVNGRSISRKNGQDQDVGASVMNAIALFVNGAPPEEKRHIEQVLKAQLNSKTTEYYHTHLPENLTSWQVITRIQQHSHLPPAPRTAGGKLYADMDRLIYQGTNYLAVVAMHSNRTGSYECINNENLKGQRTSDGMTWLYLPNDDQYRDYWPVVDSRFLPGTTSAGEQGWCDEQYRVTQLGRANIAWAGGNTLNKWASASMHLKVPTYSLKAKKSWFMAPHEMIMLGSQISSSSPAVTTIANQKISGSAKVLVDGIVLLPGEERKATQSVVLNDKGNNIIWKPLAGSSAQVSVKQRQGNWADIGTSSGKVSAQFLTIIQPHSAESDNHYAWVVFPSGSASPSVNADITLLANDAKVQAVSLPGQQVIYANFWRSATVGGIHALTPMSLIMTPTTQGYQIAVSSPRRDSRVSFQLPDNAIPFHISSDPDKRVSLNGDIVSVNMTNLRGSSYSFELSKNK

Claims

1. A microorganism, characterized in that The microorganism is a plant endophyte ( Phytobacter sp. )HAD-10, the microorganism was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on February 22, 2024, with the deposit number: CGMCC No.29875.

2. A method for degrading glycosaminoglycans, characterized in that: The method comprises using the microorganism according to claim 1.

3. The method according to claim 2, characterized in that The glycosaminoglycan contains β1-3 glycosidic bonds and / or β1-4 glycosidic bonds.

4. The method according to claim 2, characterized in that: The glycosaminoglycan comprises one or more of hyaluronic acid, dermatan sulfate, keratan sulfate, heparin, heparan sulfate or chondroitin sulfate.

5. The method according to claim 4, characterized in that The chondroitin sulfate includes one or more of CS-A, CS-B, CS-C, CS-D, CS-E, CS-F, CS-H, CS-K, CS-L or CS-M.

6. The method according to claim 2, characterized in that The method comprises culturing the microorganism according to claim 1 and mixing the culture supernatant with the glycosaminoglycan to be degraded.

7. The method according to claim 6, characterized in that The method comprises culturing the microorganism according to claim 1, collecting the supernatant, centrifuging and collecting the precipitate; and mixing the precipitate with the glycosaminoglycan to be degraded.

8. The method according to claim 2, characterized in that: The microorganism expresses the amino acid sequence shown in SEQ ID NO:

3.

9. The method according to claim 2, characterized in that: The genome of the microorganism contains the nucleotide sequence shown in SEQ ID NO:

2.

10. The method according to claim 8, characterized in that The method comprises mixing a protein comprising an amino acid sequence as shown in SEQ ID NO: 3 with glycosaminoglycan to be degraded.

11. The method according to claim 10, characterized in that The method for preparing a protein comprising the amino acid sequence shown in SEQ ID NO: 3 comprises: The nucleotide sequence comprising SEQ ID NO: 2 is introduced into the host cell to induce its expression.

12. The method according to claim 11, characterized in that The preparation method also includes purification.

13. The use of the microorganism according to claim 1, characterized in that: The applications described include: 1) Application in the degradation of glycosaminoglycans; 2) Application in the preparation of small molecule hyaluronic acid.

14. The use according to claim 13, characterized in that The glycosaminoglycan contains β1-3 glycosidic bonds and / or β1-4 glycosidic bonds.

15. The use according to claim 13, characterized in that: The glycosaminoglycan comprises one or more of hyaluronic acid, dermatan sulfate, keratan sulfate, heparin, heparan sulfate or chondroitin sulfate.

16. The use according to claim 15, characterized in that The chondroitin sulfate includes one or more of CS-A, CS-B, CS-C, CS-D, CS-E, CS-F, CS-H, CS-K, CS-L or CS-M.

17. The use according to claim 13, characterized in that: The small molecule hyaluronic acid includes hyaluronic acid oligosaccharide or GalNAc monosaccharide.

18. The use according to claim 17, characterized in that The hyaluronic acid oligosaccharide includes saturated hyaluronic acid oligosaccharide and / or unsaturated hyaluronic acid oligosaccharide.

19. The use according to claim 17, characterized in that: The GalNAc monosaccharide includes saturated GalNAc monosaccharide and / or unsaturated GalNAc monosaccharide.

20. The use according to claim 17, characterized in that The hyaluronic acid oligosaccharides include even-numbered oligosaccharides.

21. The use according to claim 20, characterized in that The even-numbered oligosaccharides include one or more of hyaluronic acid disaccharide, hyaluronic acid tetrasaccharide, hyaluronic acid hexasaccharide, hyaluronic acid octasaccharide or hyaluronic acid decasaccharide.

22. The use according to claim 17, characterized in that: The hyaluronic acid oligosaccharides include odd-numbered oligosaccharides.

23. The use according to claim 22, characterized in that The odd-numbered oligosaccharides include one or more of hyaluronic acid trisaccharide, hyaluronic acid pentasaccharide, hyaluronic acid heptasaccharide or hyaluronic acid nonasaccharide.